Biotech | December 24, 2021
Novavax and SK bioscience expand manufacturing agreement
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Autism spectrum disorder affects 78 million people and families worldwide
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
The surgery was helmed by Prof. Dr. Vishwanath Pai, Sr. Consultant, Department of Minimally Invasive Surgery, Prashanth Hospitals, Velachery
The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
The proposed scheme to include low-income NRIs under Ayushman Bharat (PM-JAY) would ensure life-long coverage for each individual along with their spouses
Subscribe To Our Newsletter & Stay Updated
